Successful financing ensures development of Adcendo’s ADC asset
Drug Discovery World
MAY 3, 2023
Michael Pehl, Chief Executive Officer of Adcendo, said: “2022 was a pivotal year for Adcendo with the expansion of our team, uPARAP ADC Development Candidate Nomination and the recent linker/payload license agreement with Duality Biologics.
Let's personalize your content